References
- Armstrong NA, James KC. (1990). Understanding experimental design and interpretation in pharmaceutics. West Sussex: Ellis Horwood Limited
- Bailly P, Grosjean P, Flammang P. (2009). Measurement of the attachment strength of brachiolaria larvae and metamorphic individuals of the sea star Asterina gibbosa by a centrifugation method. J Exp Mar Biol Ecol 372:82–90
- Beilmann B, Kubiak R, Grab P, et al. (2007). Effect of interactive ternary mixtures on dispersion characteristics of ipratropium bromide in dry powder inhaler formulations. AAPS PharmSciTech 8:E32–9
- Boraey MA, Hoe S, Sharif H, et al. (2012). Improvement of the dispersibility of spray-dried budesonide powders using leucine in an ethanol-water cosolvent system. Powder Technol 236:171–8
- British Pharmacopoeia. (2011). London: British Pharmacopoeial Commission
- El-Gendy N, Gorman EM, Munson EJ, Berkland C. (2008). Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci 98:2731–46
- Felicetti MA, Piantino F, Coury JR, Aguiar ML. (2008). Influence of removal time and particle size on the particle substrate adhesion force. Braz J Chem Eng 25:71–82
- Hamishehkar H, Emami J, Najafabadi AR, et al. (2010). Influence of carrier particle size, carrier ratio and addition of fine ternary particles on the dry powder inhalation performance of insulin-loaded PLGA microcapsules. Powder Technol 201:289–95
- Hirst PH, Newman SP, Clark DA, Hertog MGL. (2002). Lung deposition of budesonide from the novel dry powder inhaler Airmax™. Respir Med 96:389–96
- Hu TT, Zhao H, Jiang LC, et al. (2008). Engineering pharmaceutical fine particles of budesonide for dry powder inhalation (DPI). Ind Eng Chem Res 47:9623–7
- Jones MD, Harris H, Hooton JC, et al. (2008). An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances. Eur J Pharm Biopharm 69:496–507
- Lam KK, Newton JM. (1992). Influence of particle size on the adhesion behaviour of powders, after application of an initial press-on force. Powder Technol 73:117–25
- Martin A, Bustamante P, Chun AHC. (1993). Physical pharmacy. Philadelphia: Lea & Febiger
- Naikwade SR, Bajaj AN, Gurav P, et al. (2009). Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study. AAPS PharmSciTech 10:993–1012
- Nolan LM, Tajber L, McDonald BF, et al. (2009). Excipient-free nanoporous microparticles of budesonide for pulmonary delivery. Eur J Pharm Sci 37:593–602
- Pilcer G, Amighi K. (2010). Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 392:1–19
- Prota L, Santoro A, Bifulco M, et al. (2011). Leucine enhances aerosol performance of Naringin dry powder and its activity on cystic fibrosis airway epithelial cells. Int J Pharm 412:8–19
- Rabbani NR, Seville PC. (2005). The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Release 110:130–40
- Schiavone H, Palakodaty S, Clark A, et al. (2004). Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers. Int J Pharm 281:55–66
- Seville PC, Learoyd TP, Li HY, et al. (2007). Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol 178:40–50
- Sou T, Orlando L, McIntosh MP, et al. (2011). Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach. Int J Pharm 421:220–9
- Steckel H, Markefka P, teWierik H, Kammelar R. (2004). Functionality testing of inhalation grade lactose. Eur J Pharm Biopharm 57:495–505
- Szefler SJ. (1999). Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J Allergy Clin Immun 104:S175–83
- Tajber L, Corrigan DO, Corrigan OI, Healy AM. (2009a). Spray drying of budesonide, formoterol fumarate and their composites-I. Physiochem charecterisation. Int J Pharm 367:79–85
- Tajber L, Corrigan OI, Healy AM. (2009b). Spray drying of budesonide, formoterol fumarate and their composites-II. Statistical factorial design and in vitro deposition properties. Int J Pharm 367:86–96
- Telko MJ, Hickey AJ. (2005). Dry powder inhaler formulation. Respir Care 50:1209–27